Traveler's Diarrhea (TD) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Traveler's Diarrhea Emerging Therapy and TPP Insights

Thelansis's "Traveler's Diarrhea (TD) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Traveler's Diarrhea Overview

Traveler's diarrhea (TD) is an acute diarrheal illness spread through contaminated food or water. Bacterial causes include enterotoxigenic Escherichia coli, Campylobacter, Shigella and Salmonella; norovirus and protozoa, including Giardia, contribute. Symptoms include loose stools, cramps, fever, vomiting and dehydration. Most cases resolve in days, but persistent illness may reflect protozoal infection or post-infectious irritable bowel syndrome. Oral rehydration is central to care; loperamide or bismuth subsalicylate can ease symptoms in appropriate cases. Antibiotics are not recommended for mild cases. Azithromycin is preferred for severe or dysenteric disease; rifaximin and rifamycin SV are options for selected non-invasive bacterial infections. Routine antibiotic prophylaxis is discouraged due to adverse effects and resistance. Prevention research includes pathogen-specific vaccines, including investigational ETEC vaccine ETVAX; no vaccine offers broad protection against TD.

Key Highlights

• In Germany, diagnosed Traveler's Diarrhea (TD) cases are projected to increase from 3,265,903 in 2026 to 4,303,734 by 2036.
• TD is a common gastrointestinal infection associated with contaminated food and water during travel.
• Disease burden is influenced by travel exposure, sanitation, and regional infection risks.
• Unmet need remains for effective prevention and treatment, particularly for drug-resistant infections.

Market Overview

• The France TD market is projected to grow from $35M in 2026 to $65M by 2036.
• Market growth is driven by:
• Rising international travel and disease awareness
• Increasing need for effective anti-infective and preventive therapies
• Future growth will depend on improved prevention and treatments for resistant or persistent infections.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country